Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.32 |
| ▸ | RELA | Q04206 | 4/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23017918 | 0.87 | GAA (0.32) | ALDH1A1GAA | |
| SCHEMBL22965253 | 0.85 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL22965252 | 0.82 | PTPN1 (0.43) | PTPN1NFKB1NFKB2RELAHSP90AA1 | |
| SCHEMBL28485518 | 0.81 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL21454333 | 0.78 | PTPN1 (0.37) | PTPN1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL22965134 | 0.77 | PTPN1 (0.43) | PTPN1 | |
| SCHEMBL14100984 | 0.77 | PTPN1 (0.43) | PTPN1GAAHSP90AA1CYP3A4 | |
| SCHEMBL22965235 | 0.76 | ODC1 (0.40) | PTPN1SMN1; SMN2HSP90AA1CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL25453595 | 0.76 | PTPN1 (0.40) | PTPN1 | |
| SCHEMBL25453484 | 0.76 | GAA (0.31) | KDM4EALDH1A1GAAHPGDCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040106-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | Glaceum Inc. (KR) | 2021-02-11 | — | — | US | disclosed |
| WO-2019194582-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | 주식회사 글라세움 | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040106-A1 | METHOD FOR SYNTHESIZING 3-PHENYL-2,8-DIHYDROPYRANO [2,3-F] CHROMENE DERIVATIVE | HPD, CYP2J2, PAH | PTPN1 2837/4885KDM4E 802/4885ALDH1A1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.